

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

TRIAL

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT ID: NCT05987332 Phase: PHASE2 / PHASE3 Sponsor: IDEAYA Biosciences Status: Active Not Recruiting

SUMMARY

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

KEY ELIGIBILITY CRITERIA

- * Histological or cytological confirmed Metastatic Uveal Melanoma
- * HLA-A*02:01 negative
- * No prior systemic therapy in the metastatic or advanced setting regional or liver-directed therapy. Ablations or surgical resection of oligometastatic disease, and neoadjuvant or adjuvant therapy is allowed
- * Measurable disease per RECIST 1.1
- * Able to be safely administered and absorb study therapy
- * ECOG performance status 0 or 1
- * Life expectancy of e3 months
- * Adequate organ function
- * Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11
- * Concurrent malignant disease

Total sites: 68 | 0 currently recruiting